SCNI News | Roxom Stocks

1 BTC

- USD

Loading market data...

Mkt Cap

$1.0M

Volume

213.27K

Next Earnings

November 23rd

Mkt Cap

$1.2M

Volume

213.27K

Next Earnings

November 23rd

Chart Financials Earnings News About Insider Filings

Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit EuropeScinai Immunotherapeutics will lead a roundtable discussion at the 7th Dermatology Drug Development Summit Europe in Amsterdam, exploring how oral peptide and small molecule therapies may complement, compete with, or displace injectable biologic therapies in immunology and dermatology. The discussion will address key challenges including pharmacokinetic variability, bioavailability, treatment adherence, and the evolving balance between efficacy and convenience in immunotherapy development.Benzinga · May 15, 2026

Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid PriceScinai Immunotherapeutics (NASDAQ: SCNI) received a Nasdaq notification on March 12, 2026, indicating non-compliance with the minimum bid price requirement of $1.00 per share, as its closing bid price fell below this threshold for 30 consecutive business days. The company has been given 180 calendar days (until September 8, 2026) to regain compliance. If the stock closes at or above $1.00 for ten consecutive business days during this period, Nasdaq will confirm compliance and close the matter.Benzinga · Mar 16, 2026

Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TENScinai Immunotherapeutics published research validating PC111, a novel monoclonal antibody targeting pemphigus and Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), demonstrating potential as a disease-modifying therapy with a unique non-immunosuppressive mechanism.Benzinga · Jul 29, 2025

Scinai Regains Full Compliance with Nasdaq Listing RequirementsScinai Immunotherapeutics has regained full compliance with Nasdaq's listing requirements after converting $29 million of debt into equity, leaving a debt balance of $273,000. This clears the path for the company to focus on its R&D programs and CDMO business unit.Benzinga · Aug 29, 2024

Scinai Immunotherapeutics Provides Update Regarding Nasdaq ComplianceJERUSALEM, Nov. 03, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, today announced receipt of a letter from the Nasdaq Stock Market ("Nasdaq") dated November 1, 2023, regarding non-compliance with the requirement to maintain a minimum bid price of $1.00 per share.GlobeNewswire Inc. · Nov 3, 2023

Scinai Reports Third Quarter 2023 Financial Results and Provides Business UpdateJERUSALEM, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via IBN -- Scinai Immunotherapeutics Ltd (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, announced the publication today of its financial results for the third quarter ended Sept. 30, 2023 and provided a business update.GlobeNewswire Inc. · Oct 31, 2023

Scinai Immunotherapeutics to Showcase its end-to-end cGMP Biologics CDMO Services at CPHI Barcelona 2023Targeting biotech companies with drug production process development and optimization, analytical methods development, and GMP production for clinical trials Targeting biotech companies with drug production process development and optimization, analytical methods development, and GMP production for clinical trialsGlobeNewswire Inc. · Oct 4, 2023

Scinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering JERUSALEM, Sept. 19, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, today announced the closing of its previously announced registered direct offering of 1,146,552 of the Company’s American Depositary Shares (“ADSs”) (or ADS equivalents), each ADS representing four hundred (400) ordinary shares, at a purchase price of $1.16 per ADS (or ADS equivalent). In addition, in a concurrent private placement, the Company has issued unregistered warrants to purchase up to 1,146,552 ADSs representing ordinary shares. The warrants have an exercise price of $1.16 per ADS and are immediately exercisable upon issuance for a period of five and one-half years.GlobeNewswire Inc. · Sep 19, 2023

Why Novonix Shares Are Trading Higher By 27%? Here Are Other Stocks Moving In Friday's Mid-Day SessionGainers MSP Recovery, Inc. (NASDAQ: LIFW) shares jumped 127.8% to $0.1269. The company recently reported second-quarter results. AERWINS Technologies Inc. (NASDAQ: AWIN) jumped 40% to $0.1801. Know Labs, Inc. (NYSE: KNW) shares jumped 38.8% to $0.6180. Novonix Limited (NASDAQ: NVX) gained 27.4% to $2.37 after the company announced it achieved high-performance battery grade synthetic graphite production milestones with Generation 3 Furnaces at its Tennessee facility. AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) shares rose 26.3% to $0.1293 after gaining 10% on Thursday. Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) shares jumped 20.8% to $5.61 after the company announced the FDA extended its BLA Priority Review for lifileucel amid resource constraints. Faraday Future Intelligent Electric Inc. (NASDAQ: FFIE) gained 19.5% to $5.61. Faraday Future Intelligent Electric reported that one of FF's newest car owners and Developer Co-Creation Officers, Kelvin Sherman, will take delivery of his FF 91 2.0 Futurist Alliance at FF's "919 Developers AI Co-Creation Festival" to be held on Sept. 19. 5E Advanced Materials, Inc. (NASDAQ: FEAM) gained 17.6% to $2.73. Mullen Automotive, Inc. (NASDAQ: MULN) shares surged 17.4% to $0.6699 after surging 15% on Thursday. Shineco, Inc. (NASDAQ: SISI) climbed 15.8% to $0.1448. Canopy Growth Corporation (NASDAQ: CGC) climbed 15% to $1.4390. Cara Therapeutics, Inc. (NASDAQ: CARA) gained 15% to $2.38. Soleno Therapeutics, Inc. (NASDAQ: SLNO) rose 14.5% to ...Benzinga · Sep 15, 2023

Scinai Immunotherapeutics Announces $1.33 Million Registered Direct Offering JERUSALEM, Sept. 15, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, today announced that it has entered into a definitive agreement for the purchase and sale of 1,146,552 of the Company’s American Depositary Shares (“ADSs”) (or ADS equivalents), each ADS representing four hundred (400) ordinary shares, at a purchase price of yesterday’s closing price of $1.16 per ADS (or ADS equivalent), in a registered direct offering. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to 1,146,552 ADSs representing ordinary shares. The warrants will have an exercise price of $1.16 per ADS and will be immediately exercisable upon issuance for a period of five and one-half years. The closing of the offering is expected to occur on or about September 19, 2023, subject to the satisfaction of customary closing conditions.GlobeNewswire Inc. · Sep 15, 2023

SCNIScinai Immunotherapeutics Ltd. American Depositary Shares

SCNI

Pay with—

Start Trading

Available Balance0.00

Your PositionYou don't own any SCNI yet.

Related Tickers

Earnings

Mkt Cap

$1.0M

Volume

213.27K

Next Earnings

November 23rd